vs

Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and WESTAMERICA BANCORPORATION (WABC). Click either name above to swap in a different company.

WESTAMERICA BANCORPORATION is the larger business by last-quarter revenue ($63.3M vs $60.1M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). WESTAMERICA BANCORPORATION runs the higher net margin — 43.9% vs -92.6%, a 136.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -9.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -8.6%).

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

Westamerica Bancorporation is a regional bank holding company headquartered in California, U.S. It operates via its wholly owned banking subsidiary to provide full-spectrum retail and commercial banking services, including deposit products, business and consumer loans, wealth management, and payment services, primarily serving individual consumers, SMEs and local institutional clients in northern and central California.

RYTM vs WABC — Head-to-Head

Bigger by revenue
WABC
WABC
1.1× larger
WABC
$63.3M
$60.1M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+92.8% gap
RYTM
83.8%
-9.0%
WABC
Higher net margin
WABC
WABC
136.5% more per $
WABC
43.9%
-92.6%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
43.8%
-8.6%
WABC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
RYTM
RYTM
WABC
WABC
Revenue
$60.1M
$63.3M
Net Profit
$-55.6M
$27.8M
Gross Margin
88.1%
Operating Margin
-87.1%
59.8%
Net Margin
-92.6%
43.9%
Revenue YoY
83.8%
-9.0%
Net Profit YoY
-12.3%
EPS (diluted)
$-0.83
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYTM
RYTM
WABC
WABC
Q1 26
$60.1M
Q4 25
$57.3M
$63.3M
Q3 25
$51.3M
$63.7M
Q2 25
$48.5M
$64.6M
Q1 25
$32.7M
$66.4M
Q4 24
$41.8M
$69.6M
Q3 24
$33.3M
$74.1M
Q2 24
$29.1M
$74.3M
Net Profit
RYTM
RYTM
WABC
WABC
Q1 26
$-55.6M
Q4 25
$-47.5M
$27.8M
Q3 25
$-52.9M
$28.3M
Q2 25
$-46.6M
$29.1M
Q1 25
$-49.5M
$31.0M
Q4 24
$-43.3M
$31.7M
Q3 24
$-43.6M
$35.1M
Q2 24
$-32.3M
$35.5M
Gross Margin
RYTM
RYTM
WABC
WABC
Q1 26
88.1%
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Operating Margin
RYTM
RYTM
WABC
WABC
Q1 26
-87.1%
Q4 25
-82.2%
59.8%
Q3 25
-102.6%
59.5%
Q2 25
-93.4%
60.5%
Q1 25
-143.7%
63.0%
Q4 24
-98.6%
62.8%
Q3 24
-132.0%
64.5%
Q2 24
-139.2%
64.8%
Net Margin
RYTM
RYTM
WABC
WABC
Q1 26
-92.6%
Q4 25
-83.0%
43.9%
Q3 25
-103.1%
44.3%
Q2 25
-96.1%
45.0%
Q1 25
-151.4%
46.7%
Q4 24
-103.6%
45.6%
Q3 24
-131.2%
47.3%
Q2 24
-110.9%
47.8%
EPS (diluted)
RYTM
RYTM
WABC
WABC
Q1 26
$-0.83
Q4 25
$-0.73
$1.12
Q3 25
$-0.82
$1.12
Q2 25
$-0.75
$1.12
Q1 25
$-0.81
$1.16
Q4 24
$-0.71
$1.19
Q3 24
$-0.73
$1.31
Q2 24
$-0.55
$1.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYTM
RYTM
WABC
WABC
Cash + ST InvestmentsLiquidity on hand
$340.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$122.9M
$933.5M
Total Assets
$442.3M
$6.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYTM
RYTM
WABC
WABC
Q1 26
$340.6M
Q4 25
$388.9M
Q3 25
$416.1M
Q2 25
$291.0M
Q1 25
$314.5M
Q4 24
$320.6M
Q3 24
$298.4M
Q2 24
$319.1M
Stockholders' Equity
RYTM
RYTM
WABC
WABC
Q1 26
$122.9M
Q4 25
$139.1M
$933.5M
Q3 25
$148.8M
$931.6M
Q2 25
$-11.9M
$921.8M
Q1 25
$18.9M
$923.1M
Q4 24
$21.7M
$890.0M
Q3 24
$11.2M
$909.0M
Q2 24
$39.3M
$815.6M
Total Assets
RYTM
RYTM
WABC
WABC
Q1 26
$442.3M
Q4 25
$480.2M
$6.0B
Q3 25
$506.9M
$5.9B
Q2 25
$372.7M
$5.8B
Q1 25
$386.7M
$6.0B
Q4 24
$392.3M
$6.1B
Q3 24
$363.6M
$6.2B
Q2 24
$381.8M
$6.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYTM
RYTM
WABC
WABC
Operating Cash FlowLast quarter
$121.9M
Free Cash FlowOCF − Capex
$119.7M
FCF MarginFCF / Revenue
189.0%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
4.38×
TTM Free Cash FlowTrailing 4 quarters
$213.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYTM
RYTM
WABC
WABC
Q1 26
Q4 25
$-25.4M
$121.9M
Q3 25
$-26.6M
$29.4M
Q2 25
$-23.3M
$23.5M
Q1 25
$-40.4M
$42.4M
Q4 24
$-18.8M
$141.6M
Q3 24
$-25.2M
$40.6M
Q2 24
$-29.1M
$19.0M
Free Cash Flow
RYTM
RYTM
WABC
WABC
Q1 26
Q4 25
$119.7M
Q3 25
$28.7M
Q2 25
$22.8M
Q1 25
$42.2M
Q4 24
$139.8M
Q3 24
$40.1M
Q2 24
$18.6M
FCF Margin
RYTM
RYTM
WABC
WABC
Q1 26
Q4 25
189.0%
Q3 25
45.1%
Q2 25
35.3%
Q1 25
63.5%
Q4 24
201.0%
Q3 24
54.1%
Q2 24
25.0%
Capex Intensity
RYTM
RYTM
WABC
WABC
Q1 26
Q4 25
3.5%
Q3 25
1.1%
Q2 25
1.1%
Q1 25
0.3%
Q4 24
2.5%
Q3 24
0.7%
Q2 24
0.6%
Cash Conversion
RYTM
RYTM
WABC
WABC
Q1 26
Q4 25
4.38×
Q3 25
1.04×
Q2 25
0.81×
Q1 25
1.37×
Q4 24
4.47×
Q3 24
1.16×
Q2 24
0.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons